DBV Technologies SA (DBVT.OQ)
Tue, Nov 14 2017
BRIEF-DBV Technologies announces positive data from Phase IIb trial and long-term study of Viaskin Peanut
* ANNOUNCES PUBLICATION OF POSITIVE DATA FROM PHASE IIB TRIAL AND LONG-TERM STUDY OF VIASKIN PEANUT
* CASH POSITION AT SEPT. 30, 2017 EUR 170.5 MILLION VERSUS EUR 256.5 MILLION AT DEC. 31, 2016 Source text: http://bit.ly/2htbI61 Further company coverage: (Gdynia Newsroom)
* CASH AND CASH EQUIVALENTS AS OF SEPTEMBER 30, 2017, WERE EUR 170.5 MILLION, COMPARED TO EUR 256.5 MILLION AS OF DECEMBER 31, 2016 Source text for Eikon: Further company coverage: (Gdynia Newsroom)
* DBV Technologies announces topline results of phase III clinical trial in peanut-allergic patients four to 11 years of age
DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study, sending its U.S.-listed shares sharply down.
Oct 20 Drug developer DBV Technologies SA said on Friday its peanut allergy treatment did not meet the main goal in a highly anticipated late-stage study.
* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF BLINDED PERIOD IN REALISE STUDY OF VIASKIN PEANUT
* REG-DBV TECHNOLOGIES ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III EXTENSION STUDY OF VIASKIN PEANUT
* REG-DBV TECHNOLOGIES INITIATES PHASE III STUDY OF VIASKIN PEANUT IN PEANUT-ALLERGIC PATIENTS ONE TO THREE YEARS OF AGE Source text for Eikon: Further company coverage: (Gdynia Newsroom:)
* CASH POSITION: CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2017, WERE €198.7 MILLION
- Aimmune Therapeutics: Upside Into Q1 Data And Beyond
- DBV Technologies S.A. (DBVT) Presents At Citi Global Healthcare Conference - Slideshow
- Peanut Wars: Things Are Heating Up Between Aimmune Therapeutics And DBV Technologies
- Update On Aimmune Therapeutics Vs. DBV Technologies Peanut Allergy-Related Candidate Treatments
- Biotech Forum Daily Digest: What Now For Sarepta?
- Market Wisdom From A Bioscience Expert - An Integrated BioSci Interview